Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
U.S. Patent Office Upholds Key Human Embryonic Stem Cell Patent
March 15th, 2008
Geron Corporation (Nasdaq:GERN) announced that the U.S. Patent Office has upheld the validity of a key patent for human embryonic stem cells. The patent is assigned to the Wisconsin Alumni Foundation ("WARF") and is one of three related patents challenged through reexamination proceedings. Geron holds an exclusive license under these patents to develop and commercialize therapies based on three types of cells derived from human embryonic stem cells: neural cells, cardiomyocytes and pancreatic islet cells. In communicating its decision, the Patent Office issued an 82 page Action Closing Prosecution in the inter-partes reexamination of U.S. Patent Number 7,029,913. The...
Source: Law & Health Weekly (2008-03-15)
|
